Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel
Genetically modified salmon
Final stages of food safety approval for fish

Biologists in Canada are currently harvesting eggs from a genetically modified Atlantic salmon, which is in the final stages before being declared fit for human consumption.

The biologists, who work for a biotechnology firm, are going to keep the genetically modified fish – known as AquAdvantage salmon – in onshore tanks in Panama, Mexico.

They say the salmon will look just like their natural cousins, but will reach full-size in half the time. This improved growth is due to additional genes from the Pacific Chinook salmon and the ocean pout eel.

AquAdvantage salmon has already been declared to have "no significant impact" by the US food regulator, the Food and Drug Administration (FDA). This is normally the last step before official approval, however, there is still a brief period for objections.

The firm has been working on approval for AquAdvantage salmon for 17 years and, if given the green light by the FDA, the fish will be the first genetically modified animal fit for human consumption.

On the other hand, the Atlantic Salmon Federation fears that the fish, which are all female and sterile, could start breeding and disturb the ecosystem if they were to get into the wild.

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
Free webinar explores congenital heart disease in dogs

A free webinar is to provide veterinary professionals, dog breeders and pet owners an new insights into congenital heart disease.

Chris Linney, a cardiology specialist and Veterinary Cardiovascular Society (VSC) member, will present the webinar from 7.00pm to 8.30pm on Wednesday, 12 November.

Dr Linney will explore the types, causes and clinical presentation of congenital heart conditions. This will include diagnostic approaches, treatment pathways and emerging research opportunities.

The session is the third to be organised by The Kennel Club, with the VCS, following an introductory webinar and a talk on acquired heart disease. Dr Linney's webinar consists of a one-hour presentation, followed by a 30-minute question and answer session.

Dr Linney said: "This webinar will be an opportunity to deepen understanding - not just of the diseases themselves, but of how breeders, vets and owners can work together to support affected dogs and improve outcomes for future generations."

Click here to register for the webinar.